Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $222.71

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $218.63.

A number of analysts recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, May 6th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Citigroup lifted their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently made changes to their positions in the stock. Crossmark Global Holdings Inc. grew its position in shares of Krystal Biotech by 2.7% in the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company’s stock valued at $427,000 after purchasing an additional 63 shares in the last quarter. US Bancorp DE grew its position in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after buying an additional 82 shares in the last quarter. Summit Investment Advisors Inc. grew its position in Krystal Biotech by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock worth $407,000 after buying an additional 82 shares in the last quarter. Xponance Inc. grew its position in Krystal Biotech by 4.9% during the first quarter. Xponance Inc. now owns 1,873 shares of the company’s stock worth $338,000 after buying an additional 88 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC grew its position in Krystal Biotech by 6.7% during the first quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company’s stock worth $273,000 after buying an additional 95 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Stock Up 5.5%

KRYS stock opened at $139.43 on Tuesday. Krystal Biotech has a twelve month low of $131.71 and a twelve month high of $219.34. The stock’s 50 day moving average is $170.75 and its 200-day moving average is $169.76. The firm has a market capitalization of $4.03 billion, a PE ratio of 46.63 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. On average, equities research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).